Two studies published in late March demonstrate Oxford Nanopore sequencing performing clinical-grade tasks in pediatric oncology and carrier screening, extending the platform beyond research into territory held by Illumina microarrays and traditional PCR.
A preprint posted to medRxiv introduced TUCAN, a deep-learning classifier trained on 3,818 methylation samples to diagnose pediatric solid tumors and lymphomas from nanopore data. The authors noted that nanopore-based methylation analysis for these cancers had been "largely unexplored" and that the technology's real-time sequencing enables rapid CNS tumor diagnosis, addressing delays in molecular classification.
A second study, published in The Journal of Molecular Diagnostics, validated a PCR/nanopore assay for comprehensive carrier screening of cystic fibrosis, spinal muscular atrophy, and fragile X syndrome. The assay assessed CFTR, SMN1/2, and FMR1 genes across diverse populations and consolidates workflows that traditionally require multiple platforms, potentially capturing rare variants that conventional panels miss.
The studies arrive as Oxford Nanopore enters regulated clinical markets. BaseCall reported this week that the company received its first diagnostic device approval in the UK and Europe. The firm's shares rose 47% in its London IPO, valuing it at $4.6 billion, per Bloomberg.
The competitive target is Illumina, whose methylation microarrays dominate tumor classification in neuropathology. Illumina is pivoting toward clinical revenue through partnerships with Labcorp and Veritas Genetics while cutting full-year guidance and announcing $100 million in cost reductions amid a China sales ban. Oxford Nanopore's ability to perform methylation-based classification on a portable device in real time offers differentiated speed and workflow simplicity.
The TUCAN preprint has not undergone peer review, and its training set of 3,818 samples is modest compared to adult tumor classifiers. Neither study disclosed Oxford Nanopore funding or involvement. The carrier screening validation will need replication across larger cohorts before clinical labs displace entrenched workflows. Whether Oxford Nanopore pursues FDA or CE-IVD clearance for these applications and whether reference laboratories adopt the methodologies remain open questions.